174 related articles for article (PubMed ID: 37672753)
1. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.
Matulewicz RS; Benfante N; Funt SA; Feldman DR; Carver B; Doudt A; Knezevic A; Sheinfeld J
J Urol; 2024 Jan; 211(1):80-89. PubMed ID: 37672753
[TBL] [Abstract][Full Text] [Related]
2. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.
Daneshmand S; Cary C; Masterson T; Einhorn L; Adra N; Boorjian SA; Kollmannsberger C; Schuckman A; So A; Black P; Bagrodia A; Skinner E; Alemozaffar M; Brand T; Eggener S; Pierorazio P; Stratton K; Nappi L; Nichols C; Luo C; Li M; Hu B
J Clin Oncol; 2023 Jun; 41(16):3009-3018. PubMed ID: 36913642
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS).
Heidenreich A; Paffenholz P; Hartmann F; Seelemeyer F; Pfister D
Eur Urol Oncol; 2024 Feb; 7(1):122-127. PubMed ID: 37438222
[TBL] [Abstract][Full Text] [Related]
4. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer.
Hiester A; Nini A; Arsov C; Buddensieck C; Albers P
J Urol; 2020 Dec; 204(6):1242-1248. PubMed ID: 32717162
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.
Nicolai N; Nazzani S; Tesone A; Macchi A; Piva L; Salvioni R; Stagni S; Torelli T; Agostini E; Celso F; Giannatempo P; Procopio G; Avuzzi B; Lanocita R; Cattaneo L; Catanzaro M; Biasoni D
Tumori; 2023 Aug; 109(4):379-386. PubMed ID: 35915559
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy.
Douglawi A; Calaway A; Tachibana I; Panizzutti Barboza M; Speir R; Masterson T; Adra N; Foster R; Einhorn L; Cary C
J Urol; 2020 Jul; 204(1):96-103. PubMed ID: 32003612
[TBL] [Abstract][Full Text] [Related]
8. Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?
Tachibana I; Alabd A; Tong Y; Piroozi A; Mahmoud M; Kern SQ; Masterson TA; Adra N; Foster RS; Hanna NH; Einhorn LH; Cary C
J Clin Oncol; 2023 Aug; 41(23):3930-3938. PubMed ID: 36730902
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma.
Hu B; Shah S; Shojaei S; Daneshmand S
Clin Genitourin Cancer; 2015 Aug; 13(4):e265-e269. PubMed ID: 25682512
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).
Hiester A; Che Y; Lusch A; Kuß O; Niegisch G; Lorch A; Arsov C; Albers P
Eur Urol; 2023 Jul; 84(1):25-31. PubMed ID: 36372627
[TBL] [Abstract][Full Text] [Related]
11. Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?
Beck SD; Foster RS; Bihrle R; Cheng L; Donohue JP
J Urol; 2005 Oct; 174(4 Pt 1):1287-90; discussion 1290. PubMed ID: 16145394
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
13. Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.
Al-Ahmadie HA; Carver BS; Cronin AM; Olgac S; Tickoo SK; Fine SW; Gopalan A; Stasi J; Rabbani F; Bosl GJ; Sheinfeld J; Reuter VE
Urology; 2013 Dec; 82(6):1341-6. PubMed ID: 24094656
[TBL] [Abstract][Full Text] [Related]
14. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
[TBL] [Abstract][Full Text] [Related]
15. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
16. Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?
Overs C; Beauval JB; Mourey L; Rischmann P; Soulié M; Roumiguié M; Doumerc N
World J Urol; 2018 Apr; 36(4):655-661. PubMed ID: 29353314
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience.
Hyams ES; Pierorazio P; Proteek O; Sroka M; Kavoussi LR; Allaf ME
J Urol; 2012 Feb; 187(2):487-92. PubMed ID: 22177913
[TBL] [Abstract][Full Text] [Related]
18. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.
Rice KR; Beck SD; Bihrle R; Cary KC; Einhorn LH; Foster RS
J Urol; 2014 Nov; 192(5):1397-402. PubMed ID: 24813309
[TBL] [Abstract][Full Text] [Related]
20. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
